ODDB.org: Open Drug Database | Medikamente

Suchresultat - FI zu RYSTIGGO

Fachinformation zu RYSTIGGO:

UCB-Pharma SA

L04AG16 -

ATC-DDD Version 2016. Source: WHO

L - Antineoplastic and Immunomodulating Agents

This group comprises preparations used in the treatment of neoplastic diseases, and immunomodulating agents.
Corticosteroids for systemic use, see H02.

L04 - Immunosuppressants

Immunosuppressants are defined as agents that completely or partly suppress one or more factors in the immunosystem.

L04A - Immunosuppressants

This group comprises immunosuppressants excl. corticosteroids.

The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication.

L04AG - Monoclonal Antibodies

Monoclonal antibodies with a mechanism of action described and matching another ATC group in L04A are classified in the corresponding group e.g. L04AB - Tumor necrosis factor alpha (TNF-?) inhibitors, L04AC - Interleukin inhibitors or L04AJ - Complement inhibitors. All other immunosuppressant monoclonal antibodies are classified here.
Low strength products of ofatumumab used in the treatment of relapsing multiple sclerosis (RMS) are classified in this group, while high strength products for treatment of chronic lymphocytic leukaemia (CLL) are classified in L01FA.

The DDD for muromonab-CD3 is based on combination therapy in acute allograft rejection.
The DDD for efalizumab is based on the treatment of psoriasis.
The DDDs for natalizumab and alemtuzumab are based on the treatment of multiple sclerosis.
The DDD for alemtuzumab is based on the average calculated daily dose in the first two years (year 1 and 2) when all patients receive medication.
The DDD for ocrelizumab is based on the intravenous (IV) formulation.

L04AG16 -

2026	©ywesee GmbH